Lake Street analyst Ben Klieve lowered the firm’s price target on Bioceres (BIOX) to $5 from $8 and keeps a Buy rating on the shares. Q4 results were materially below all estimates in each segment, though the firm believes FY25 will prove to be an EBITDA trough and sees value in the next-generation products throughout Bioceres’ portfolio, the analyst tells investors in a post-earnings note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIOX:
- Bioceres downgraded to Hold from Buy at Canaccord
- Bioceres Crop Solutions: Hold Rating Amid Macroeconomic Challenges and Strategic Shift
- Bioceres Crop Solutions Faces Challenging Fiscal Year
- Bioceres Crop Solutions Earnings Call Highlights Challenges and Recovery
- Bioceres Crop Solutions Faces Challenging FY25 Amid Argentine Market Pressures